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Abstract Introduction Rapid HIV serological tests are a
cost-effective, point-of-care test among HIV exposed
infants but cannot distinguish between maternal and infant
antibodies. The lack of data on the timing of decay of
maternal antibodies in young infants hinders the potential
use of rapid tests in exposed infants. We aimed to deter-
mine the time to seroreversion for two commonly used
rapid tests in a prospective cohort of HIV-exposed
breastfeeding infants ages 3–18 months of life. Methods
We collected data on the performance of two commonly
used rapid tests (Determine and Unigold) in Malawi
between 2008 and 2012 or at the University of North
Carolina between 2014 and 2015. Time to seroreversion
was estimated for both rapid tests using the Kaplan–Meier
product limit estimator which allows for interval censored
data. Results At 3 months of age, 3 % of infants had
seroreverted according to Determine and 7 % had serore-
verted according to Unigold. About one in four infants had
achieved seroreversion by 4 months using Unigold, but
only about one in twelve infants by 4 months when using
Determine. More than 95 % of all infants had seroverted by
7 months according to Unigold and by 12 months
according to the Determine assay. Discussion We show
that the time of seroreversion depends greatly on the type
of test used. Our results highlight the need for recom-
mendations to specify the timing and type of test used in
the context of infant HIV detection in resource-poor set-
tings, and base the interpretation of test result on knowl-
edge of time to seroreversion of the selected test.
Keywords Breastfeeding  Diagnostic testing  Early
infant diagnosis  HIV transmission  Prevention of mother-
to-child transmission
Significance
The need for an accurate rapid, point-of-care HIV test for
breastfeeding infants in resource-limited settings is now
greater than ever, given the recommendation for prolonged
breastfeeding and increasing access to life-saving treatment
for HIV-infected infants. However, circulating maternal
HIV antibodies complicates the interpretation of rapid
serological tests in HIV exposed, uninfected infants. The
lack of data on the timing of decay of maternal antibodies
in young infants hinders the potential use of rapid tests in
exposed infants. We show that the time of seroreversion
depends greatly on the type of test used.
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Introduction
The need for an accurate rapid, point-of-care HIV test for
breastfeeding infants in resource-limited settings is now
greater than ever, given the recommendation for prolonged
breastfeeding and increasing access to life-saving treatment
for HIV-infected infants. Since 2010, the World Health
Organization (WHO) breastfeeding guidelines (WHO
2010) encourage women to exclusively breastfeed for the
first six months of life and continue breastfeeding
throughout the first two years of life, whereas previously,
HIV positive mothers were encouraged to use formula
feeding starting at age 6 months (WHO 2006). In light of
the continued risk of vertical HIV infection that accom-
panies such prolonged breastfeeding, consensus statements
have concluded that a prompt and definitive HIV diagnosis
among infants is crucial for timely initiation of life-saving
antiretroviral treatment (Chiappini et al. 2006; Prendergast
et al. 2008; Violari et al. 2008).
For early infant diagnosis (EID) of HIV infection, the
WHO recommends a virological assay. Use of virological
assays in resource-limited settings is limited by high costs
and logistical constraints, as these assays require trans-
portation to a centralized laboratory and thus a return visit
by the mothers for test results. Rapid serological tests could
be a cheaper, point-of-care alternative. The lack of data on
the timing of decay of maternal antibodies in young infants
hinders the potential use of rapid tests for identification of
new HIV infections in breastfeeding infants. Furthermore,
circulating maternal HIV antibodies in HIV exposed,
uninfected infants complicates the interpretation of rapid
serological tests due to the difficulty in distinguishing
between HIV antibodies produced by an HIV-infected
infant and maternal HIV antibodies in an HIV exposed,
uninfected infant (Moodley et al. 1995; Sirinavin and
Atamasirikul 2000).
We aimed to determine the time to seroreversion for two
commonly used rapid tests in a cohort of HIV-exposed
breastfeeding infants ages 3–18 months of life.
Methods
Between May 2008 and March 2012, we prospectively
collected data on two HIV rapid tests, Unigold and
Determine in two healthcare centers of the Blantyre
region of Malawi as part of a community-based cohort
study examining the effect of HIV infection and HIV
exposure on neurodevelopment. During that period, both
clinics provided HIV counseling and testing to all pregnant
women and offered single dose nevirapine or zidovudine
treatment to women who were HIV infected and to infants
born to HIV infected mothers. Option B? was not imple-
mented throughout the country during this time period.
Children were included if they were HIV negative by HIV
DNA PCR (version 1.5 of the Amplicor HIV-1 DNA,
Roche, Basel, Switzerland) at age 6 weeks or the age
closest to that time (median age of enrollment was
6.4 weeks, standard deviation 2.6 weeks). Caregivers were
asked to bring these infants to the study clinic at age
10 weeks and every 3 months between age 14 weeks and
18 months. At all timepoints, dried blood spots were col-
lected and stored for future HIV DNA PCR assays, and a
venous whole blood sample was taken and stored at
B-70 C. A positive HIV DNA PCR result was confirmed
through a second HIV DNA PCR assay or an HIV RNA
viral load assay. HIV antibody testing was not conducted
after a confirmed positive HIV DNA PCR result. Starting
in February 2009, an additional fingerprick was performed
for point-of-care Unigold and Determine rapid HIV tests
at age 6, 9, 12, 15, and 18 months in real-time during the
study visit. To obtain data at age 3 months, the Unigold
and Determine rapid tests were performed on stored
blood. Missing data at other time points, due to failure to
perform the rapid test at point-of-care or assay stock-outs,
were also resolved by performing rapid HIV tests on stored
blood. Stored samples were allowed to thaw per manu-
facturers instructions, and both rapid tests were performed
simultaneously by a single operator at a research laboratory
at the University of North Carolina. Weakly positive rapid
tests results were reported as positive. The proportion of
samples evaluated on stored blood at UNC was 98 % at
3 months, 33 % at 6 months, 32 % at 9 months, 41 % at
12 months, 25 % at 15 months, and 14 % at 18 months.
HIV infection status of all infants was confirmed or ruled
out with an HIV DNA PCR test at each timepoint.
The primary endpoint, time to seroreversion, was
defined as the first occurrence of a negative HIV rapid test,
confirmed by a negative HIV PCR test. Because rapid tests
were performed at 3-month intervals, the exact time of
seroreversion was not observed but only known to have
occurred in the time interval between the last positive rapid
test and the first negative rapid test. The distribution of age
of seroreversion was estimated for both Determine and
Unigold using the extension of the Kaplan–Meier product
limit estimator which allows for interval censored data via
SAS PROC ICLIFETEST (Peto 1973; Turnbull 1976;
Wellner and Zhan 1997) (SAS Institute). Observations
were right censored at the first occurrence of an incident
HIV infection, death, or loss to follow-up, if these occurred
prior to seroreversion, or at the end of the 18 month follow-
up period. Bootstrap sampling was used to calculate cor-
responding 95 % confidence intervals. We accounted for
competing risks (Aalen and Johansen 1978) of death or
HIV infection in the infant. Since these results were similar
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to the results without accounting for competing risks, all
results presented are unaccounted for competing risks
(Satagopan et al. 2004).
The University of Malawi College of Medicine
Research and Ethics Committee and the University of
North Carolina at Chapel Hill Institutional Review Board
approved the study protocol. All mothers provided written
informed consent and permission for participation of their
infant.
Results
Of the 121 infants included in the analysis, 51 % were
female and 49 % were male. The median age of the mother
at the time of delivery was 27 years. Most women self-
reported no PMTCT for themselves (71 %), and 80 % of
infants receiving single dose nevirapine or zidovudine the
regimens in use and available during the study period.
Approximately 54 % of infants were exclusively breastfed
at month 3 and only 18 % were exclusively breastfed at
month 6. Any breastfeeding, including mixed feeding,
progressively declined with 87 % of infants breastfeeding
at 3 months, 69 % at 6 months, 45 % at 9 months, 39 % at
12 months, 26 % at 15 months, and 17 % at 18 months of
age. During follow-up, 21 (17 %) infants were diagnosed
with incident HIV infection.
The estimated probability of seroreversion between age 3
and 18 months, stratified by rapid test, is presented in
Table 1. At 3 months of age, 3 % of infants had seroreverted
according to Determine and 7 % had seroreverted according
to Unigold. About one in four infants had achieved serore-
version by 4 months using Unigold, but only 8 % by
4 months when using Determine. More than 95 % of all
infants had seroverted by 7 months according to Unigold and
by 12 months according to the Determine assay.
Discussion
Circulating maternal HIV antibodies complicates the
interpretation of rapid serological tests in HIV exposed,
uninfected infants. In this cohort of HIV-exposed infants,
we show that the time of seroreversion depends greatly on
the type of test used, with time of seroreversion occurring
at a much younger age for the Unigold assay compared to
the Determine assay.
The WHO EID guidelines only recommend rapid tests
for diagnostic purposes starting at age 18 months. Our data
suggest that the Unigold assay could be used from month 7
onwards to exclude infant HIV infection in HIV-exposed,
breastfeeding infants, as maternal antibodies could no
longer be detected by the Unigold assay among 7-month
old infants. From a mother’s perspective, an HIV negative
diagnosis in her infant is emotionally important and could
motivate her to adhere to her antiretroviral therapy during
the remaining breastfeeding period. For healthcare provi-
ders, documentation of seroreversion would increase con-
fidence in the interpretation of HIV screening by rapid tests
during the subsequent months of breastfeeding, as a posi-
tive rapid test after documented seroreversion will strongly
suggest incident infection demanding further investigation
and a negative test after a prior negative test strongly
suggests that the child has remained free of HIV.
While data are limited, data on time to seroreversion
greatly differ between different rapid tests and across
studies of the same rapid test. In industrialized countries
using Western Blot assays, median ages at seroreversion
were 7–12 months (Andiman et al. 1960; Arico et al. 1991;
Chantry et al. 1995). South African infants had docu-
mented seroreversion in 98 % for Unigold and 50 % for
Determine at 12 months (Sherman et al. 2008), with the
Determine results lower than the 95 % for Determine we
observed at age 12 months. In another cross-sectional
Table 1 Estimated probability
of seroreversion at a certain age,
by rapid test
Age (months) Determine probability (95 % CI) Unigold probability (95 % CI)
3 3.1 (0.0, 6.7) 7.4 (1.0, 13.7)
4 8.1 (1.0, 14.5) 23.9 (14.5, 33.4)
5 16.5 (9.1, 23.9) 33.3 (30.0, 36.4)
6 24.9 (17.6, 32.3) 67.3 (61.7, 72.9)
7 72.4 (71.3, 73.4) 98.9 (96.9, 100.0)
8 72.4 (71.3, 73.4) 99.2 (97.1, 100.0)
9 85.5 (82.3, 88.7) 99.3 (97.3, 100.0)
10 90.4 (87.3, 93.6) 99.4 (97.4, 100.0)
11 92.3 (89.4, 95.1) 99.5 (97.6 (100.0)
12 95.1 (92.2, 97.9) 99.7 (97.7, 100.0)
13 100.0 (95.1, 100.0) 99.8 (97.8, 100.0)
CI confidence interval
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South African study, the proportion of HIV exposed
uninfected infants (n = 11) who seroreverted according to
Determine was 2.6 % between ages of 2–4 months of age,
13 % between ages of 4–6 months, and 82 % between the
ages of 8–10 months of age (Sherman et al. 2012), with the
latter percentage higher than the 72 % observed in our
cohort. Reasons for differences include usage of whole
blood versus serum and small sample sizes between studies
and differences in postmenstrual age at delivery, maternal
HIV immunoglobulin G (IgG) concentrations, maternal
HIV severity, and maternal viral load and CD4 count, as
these factors are strong determinants of the amount of
placental immunoglobulin G (IgG) transfer (Saji et al.
1999; Malek et al. 1989; Palmeira et al. 2012; van den Berg
et al. 2011; Farquhar et al. 1999; Scott et al. 2005).
Several limitations to our study need to be mentioned.
First, seroreversion rates found in our study may have been
inflated due to testing on stored blood (Sherman et al. 2008;
Sherman et al. 2012; Pavie et al. 2010), as higher sensitivi-
ties have been documented when rapid tests were performed
on stored blood as compared to fresh serum (Sherman et al.
2012; Saji et al. 1999). However, we do not expect the use of
stored blood to impact the results substantially as 60 % of all
testing was conducted in Malawi in real-time. Second, many
countries are moving towards provision of HAART for all
HIV positive women (under Option B?) and studies have
suggested longer times to seroreversion in the presence of
HAART (Gutierrez et al. 2012).
In conclusion, our results highlight the need for rec-
ommendations to specify the timing and type of test used in
the context of infant HIV detection in resource-poor set-
tings, and base the interpretation of test result on knowl-
edge of time to seroreversion of the selected test. Further
research is needed in different resource-poor settings to
estimate the time of seroreversion, identify the optimal
rapid test for repeat screening of breastfeeding infants, and
better understand how determinants of seroreversion in
HIV exposed infants may differ between settings.
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